Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas W Lycan

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Clinical Lung Cancer|January 10, 2020
Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non-Small-Cell Lung Cancer in Clinical PracticeLaurie E Steffen McLouth, Thomas W Lycan, Beverly J Levine, et al.
JAMA Otolaryngology-- Head & Neck Surgery|June 18, 2026
Pembrolizumab Plus Quad-Shot Radiotherapy for Recurrent, Unresectable, or Metastatic Head and Neck Cancer: A Nonrandomized Clinical TrialRyan T Hughes, Sydney Smith, Thomas W Lycan, et al.
Future Oncology (London, England)|May 18, 2023
Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancerRyan T Hughes, Rediet R Gebeyehu, John Mason Kalada, et al.
The Journal of Experimental Medicine|June 5, 2020
Nicotine promotes brain metastasis by polarizing microglia and suppressing innate immune functionShih-Ying Wu, Fei Xing, Sambad Sharma, et al.
The Journal of Experimental Medicine|February 5, 2026
Correction: Nicotine promotes brain metastasis by polarizing microglia and suppressing innate immune functionShih-Ying Wu, Fei Xing, Sambad Sharma, et al.
JCO Oncology Practice|February 4, 2021
Unmet Care Needs and Financial Hardship in Patients With Metastatic Non-Small-Cell Lung Cancer on Immunotherapy or Chemoimmunotherapy in Clinical PracticeLaurie E McLouth, Chandylen L Nightingale, Beverly J Levine, et al.
Future Oncology (London, England)|May 28, 2025
Impact of comorbidity on immune-related adverse events and survival in older cancer patients treated with immunotherapyAlyssa A Guo, Mary-Peyton Knapp, Joni K Evans, et al.
Frontiers in Oncology|September 16, 2022
Early [18]FDG PET/CT scan predicts tumor response in head and neck squamous cell cancer patients treated with erlotinib adjusted per smoking statusMercedes Porosnicu, Anderson O'Brien Cox, Joshua D Waltonen, et al.
Therapeutic Advances in Medical Oncology|January 22, 2024
Study protocol: phase II study to evaluate the effect of cetuximab monotherapy after immunotherapy with PD-1 inhibitors in patients with head and neck squamous cell cancerKimberly M Burcher, Chance H Bloomer, Elena Gavrila, et al.
Molecular Oncology|October 27, 2020
SMARCA4 mutations in KRAS-mutant lung adenocarcinoma: a multi-cohort analysisLiang Liu, Tamjeed Ahmed, William J Petty, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Clinical Lung Cancer|January 10, 2020
Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non-Small-Cell Lung Cancer in Clinical PracticeLaurie E Steffen McLouth, Thomas W Lycan, Beverly J Levine, et al.
JAMA Otolaryngology-- Head & Neck Surgery|June 18, 2026
Pembrolizumab Plus Quad-Shot Radiotherapy for Recurrent, Unresectable, or Metastatic Head and Neck Cancer: A Nonrandomized Clinical TrialRyan T Hughes, Sydney Smith, Thomas W Lycan, et al.
Future Oncology (London, England)|May 18, 2023
Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancerRyan T Hughes, Rediet R Gebeyehu, John Mason Kalada, et al.
The Journal of Experimental Medicine|June 5, 2020
Nicotine promotes brain metastasis by polarizing microglia and suppressing innate immune functionShih-Ying Wu, Fei Xing, Sambad Sharma, et al.
The Journal of Experimental Medicine|February 5, 2026
Correction: Nicotine promotes brain metastasis by polarizing microglia and suppressing innate immune functionShih-Ying Wu, Fei Xing, Sambad Sharma, et al.
JCO Oncology Practice|February 4, 2021
Unmet Care Needs and Financial Hardship in Patients With Metastatic Non-Small-Cell Lung Cancer on Immunotherapy or Chemoimmunotherapy in Clinical PracticeLaurie E McLouth, Chandylen L Nightingale, Beverly J Levine, et al.
Future Oncology (London, England)|May 28, 2025
Impact of comorbidity on immune-related adverse events and survival in older cancer patients treated with immunotherapyAlyssa A Guo, Mary-Peyton Knapp, Joni K Evans, et al.
Frontiers in Oncology|September 16, 2022
Early [18]FDG PET/CT scan predicts tumor response in head and neck squamous cell cancer patients treated with erlotinib adjusted per smoking statusMercedes Porosnicu, Anderson O'Brien Cox, Joshua D Waltonen, et al.
Therapeutic Advances in Medical Oncology|January 22, 2024
Study protocol: phase II study to evaluate the effect of cetuximab monotherapy after immunotherapy with PD-1 inhibitors in patients with head and neck squamous cell cancerKimberly M Burcher, Chance H Bloomer, Elena Gavrila, et al.
Molecular Oncology|October 27, 2020
SMARCA4 mutations in KRAS-mutant lung adenocarcinoma: a multi-cohort analysisLiang Liu, Tamjeed Ahmed, William J Petty, et al.
Pageof 4